Randomized trial data support the use of either TNF or IL-17 inhibitors to treat axial spondyloarthritis, based on patient ...

Multiple TNF inhibitors, as well as interleukin-17 blockers such as secukinumab (Cosentyx) and Janus kinase (JAK) inhibitors ...

Upadacitinib treatment was associated with reduced non-nociceptive pain among patients with axSpA, including both neuropathic and nociplastic types.

An Indian researcher at Yale has developed the A-tool, a simple online questionnaire to help detect axial spondyloarthritis, a chronic back pain condi ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to pr ...

MoonLake Immunotherapeutics ( ($MLTX) ) has shared an announcement. On November 5, 2025, MoonLake Immunotherapeutics announced promising results ...

Augurex’s Spinestat diagnostic test earned the FDA’s breakthrough device designation. Spinestate is a 14-3-3eta autoantibody multiplex immunoassay test for diagnosing axial spondyloarthritis, ...

MoonLake intends to use the net proceeds from this offering together with its existing cash, cash equivalents and marketable securities, to fund the research and development of sonelokimab and for ...

Impaired lung function is associated with both the prevalence and incidence of SpA, with the strongest effects observed in axSpA and AS.

Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.

Of patients with no draining tunnels at baseline, 87.8% still had none at one year, and 90.8% at three years* – indicating sustained symptom relief in these lesions Clinically meaningful improvements ...